Metachromatic leukodystrophy juvenile form results from biallelic pathogenic variants in the ARSA gene, which encodes the lysosomal enzyme arylsulfatase A. When arylsulfatase A activity is severely reduced or absent, sulfatides accumulate in Schwann cells and oligodendrocytes, causing progressive demyelination of central and peripheral nervous system axons. GeneReviews describes three functional classes of ARSA alleles: disease-causing alleles (ARSA-MLD), pseudodeficiency alleles (ARSA-PD), and compound alleles combining both variant types. Individuals with homozygous or compound heterozygous ARSA-MLD genotypes typically show 0%–10% of normal enzyme activity and develop MLD. The pseudodeficiency genotype results in biochemically reduced enzyme activity detectable in laboratory assays but does not cause clinical disease. GeneReviews further notes that genotype partly predicts clinical subtype, with the late-infantile form generally associated with earlier-null alleles, while juvenile and adult forms tend to be associated with alleles retaining some residual enzyme activity.

Diagnosis of MLD is established through laboratory and neuroimaging assessment. According to GeneReviews, confirmatory evaluation includes measurement of arylsulfatase A enzyme activity in leukocytes—which is typically less than 10% of normal values in affected individuals—combined with measurement of urinary sulfatide excretion and molecular genetic testing to identify biallelic pathogenic ARSA variants. Brain MRI is a central diagnostic tool, showing diffuse symmetric periventricular white matter hyperintensity on T2-weighted sequences; in early disease, abnormalities typically show parieto-occipital predominance with sparing of subcortical U-fibers, and the affected white matter may exhibit a characteristic tigroid pattern. Nerve conduction studies document peripheral nervous system involvement through reduced nerve conduction velocities. GeneReviews notes that MLD may be suspected in individuals presenting with progressive neurological dysfunction following normal early development, particularly when neuroimaging reveals a leukodystrophy pattern consistent with symmetric periventricular demyelination.

There is no FDA-approved pharmacological treatment listed in current clinical data for metachromatic leukodystrophy juvenile form. According to GeneReviews, hematopoietic stem cell transplantation (HSCT)—either allogeneic using donor-derived cells or autologous using gene-corrected hematopoietic stem cells—represents an available therapeutic approach targeting the primary disease mechanism. GeneReviews emphasizes that HSCT offers the greatest potential benefit for presymptomatic individuals or those in very early disease stages; the procedure is not considered appropriate for individuals with significant neurological impairment, as it cannot reverse established myelin damage. Supportive care addresses specific manifestations including spasticity management, seizure control, nutritional support, and physical and occupational therapy. Investigational gene therapy approaches—including autologous HSCT with gene-corrected cells and in vivo gene delivery via intrathecal routes—are under active clinical investigation. An orphan designation was previously granted for recombinant human arylsulfatase A replacement therapy but that designation has since been withdrawn.

The juvenile form of MLD follows a progressive course leading to loss of all motor, sensory, and cognitive functions. GeneReviews documents that disease progression in juvenile-onset cases typically extends over several years to decades—generally slower than the late-infantile form but variable across individuals. Disease course within families is usually similar, though exceptions are reported in the literature. Early disease stages may involve subtle cognitive or behavioral changes before neurological deterioration becomes clinically apparent. As demyelination advances, affected individuals develop complete dependency for all activities of daily living. GeneReviews notes that presymptomatic individuals who undergo HSCT may have an altered disease trajectory compared to those treated after symptom onset, based on published transplantation series; however, most individuals diagnosed with MLD have no family history and are thus identified after symptom onset.

Research into MLD juvenile form is active across multiple investigational domains. A classified publication digest spanning over 100 publications encompasses epidemiology, natural history, gene therapy, and biomarker research. According to GeneReviews, multiple gene therapy strategies are under active clinical investigation, including in vivo gene therapy via intrathecal delivery and autologous HSCT with gene-corrected hematopoietic progenitor cells; these approaches are being evaluated primarily in presymptomatic populations given the demonstrated association between early intervention and outcome. Active clinical trials include newborn screening research, interventional gene therapy protocols at various phases, and natural history characterization studies. GeneReviews notes that therapies capable of reaching the brain rapidly after symptom onset represent a central unmet need in the MLD research agenda, given that most affected individuals are diagnosed after the presymptomatic window for HSCT has passed.